Hormone replacement therapy linked to lower COVID-19 mortality risk

Receiving hormone replacement therapy within 6 months of a COVID-19 diagnosis was associated with a reduction in mortality, according to researchers.
The findings mark a step forward in understanding the sex-based disparity in COVID-19 mortality rates, researchers said.
Based on the findings, Hajira Dambha-Miller, MRCGP, PhD, FHEA, a general practitioner and a National Institute for Health and Care Research Clinical Lecturer in Primary Care at the University of Southampton, and colleagues reported in Family Practice that there is no reason to discontinue hormone replacement therapy (HRT) due to

Receiving hormone replacement therapy within 6 months of a COVID-19 diagnosis was associated with a reduction in mortality, according to researchers.
The findings mark a step forward in understanding the sex-based disparity in COVID-19 mortality rates, researchers said.
Based on the findings, Hajira Dambha-Miller, MRCGP, PhD, FHEA, a general practitioner and a National Institute for Health and Care Research Clinical Lecturer in Primary Care at the University of Southampton, and colleagues reported in Family Practice that there is no reason to discontinue hormone replacement therapy (HRT) due to